Already a DIA Member? Sign in. Not a member? Join.

Iniciar sesión

¿Ha olvidado su ID de usuario? or ¿Ha olvidado su contraseña?

Not a Member?

Create Account and Join

Capital Hilton

28 oct 2024 8:30 a.m. - 30 oct 2024 12:40 p.m.

1001 16th Street NW, Washington, DC 20036-5794

DIA/FDA Oligonucleotide-Based Therapeutics Conference

Session 10 Track 3: Streamlining Oligonucleotide Development with Platform Approaches Roundtable

Session Chair(s)

Dominik  Altevogt, PhD

Dominik Altevogt, PhD

Associate Director Regulatory Affairs CMC

Novartis, Switzerland

This session will discuss the benefits of using platform approaches in the development of therapeutic oligonucleotides, including streamlining processes and expediting regulatory submissions. The session will feature mini talks on platform strategies, where experts will share their insights and experiences. Following the talks, there will be a round table discussion with regulators and industry experts on the challenges and opportunities of implementing these strategies. The discussion will provide a forum for an open exchange of ideas and perspectives, and participants will have the opportunity to engage with the experts and learn from their experiences.

Learning Objective : At the conclusion of this session, participants should be able to:
  • Identify benefits of using platform approaches in the development of therapeutic oligonucleotides
  • Recognize the regulatory challenges associated with using platform approaches
  • Apply concepts from the session to enable the use of platform approaches

Speaker(s)

Brian  Pack, PhD

A Novel Approach to Stability Platform Definition In Support of Clinical Trial Dating

Brian Pack, PhD

Eli Lilly, United States

Associate Vice President

Joshua Leo Brooks, PhD

Platform Approach to siRNA Drug Substance Manufacturing Process Validation

Joshua Leo Brooks, PhD

Alnylam Pharmaceuticals, United States

Director of Process Validation

Lawrence  Perez, PhD

Speaker

Lawrence Perez, PhD

FDA, United States

Senior Pharmaceutical Quality Assessor, CDER

Yannick  Fillon, PhD

Operational Range Assessment for Oligonucleotide Characterization

Yannick Fillon, PhD

Biogen, United States

Head of Oligonucleotide Process Chemistry

Brian  Dooley, MPharm, MSc

Panel Discussion:

Brian Dooley, MPharm, MSc

European Medicines Agency, Netherlands

Pharmaceutical Quality Senior Specialist

Andreas  Kuhn, PhD

Towards a Bracketing / Matrix approach for PPQ Covering a Defined mRNA Sequence and Process Space

Andreas Kuhn, PhD

Biontech SE, Germany

Senior Vice President RNA Biochemistry & CMC Development

¿Tiene una cuenta?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.